CESSATECH A/S
NNGM:CESSA8.86
DKK
+0.08
(+0.91%)
ISIN
DK0061411964
Return %
Stock
S&P 500
1Y
-13.31
14.20
3Y
111.46
81.12
5Y
-45.88
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jes Trygved
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Copenhagen Denmark
- IPO Date
- Dec 16, 2020
- Website
- cessatech.com
- Similar Companies
- Business
- Cessatech A/S is a clinical-stage biopharmaceutical company that develops and commercializes non-invasive, evidence-based specialty medicines designed for paediatric acute and emergency hospital care. Founded in 2020 and headquartered in Hellerup, Denmark, the company operates within the biotechnology and healthcare sectors, targeting the unmet medical needs of infants, children, and adolescents. Cessatech operates primarily across Europe and North America through a collaborative, asset-centric business model. The company's clinical pipeline includes CT001, a proprietary fixed-dose nasal spray combination of sufentanil and ketamine indicated for acute and procedural pain management in children aged 1 to 17 years; CT002, a non-invasive intranasal sedative designed for procedural sedation during diagnostic examinations and minor medical procedures such as MRI scans; CT003, a sterile, needle-free topical local anaesthetic gel in pre-clinical development for laceration repair and open wound treatment in emergency settings; and CT004, an intravenous melatonin formulation in Phase II clinical trials for the prevention and treatment of post-operative emergence delirium in paediatric patients undergoing general anaesthesia. In recent corporate developments, Cessatech entered into a 50/50 commercial collaboration with Ventis Pharma alongside manufacturing partner STAQ Pharma to produce and distribute CT001 in the United States market through 503B outsourcing compounding channels, achieving the release of its initial commercial batches. Concurrently, the company secured an exclusive licensing and commercialization partnership with Proveca Ltd to distribute CT001 throughout Europe and other international territories outside the United States, advancing regulatory filings for a Paediatric-Use Marketing Authorisation with the European Medicines Agency. To finance its commercial launch and ongoing clinical programs, Cessatech also executed a directed share capital increase to strengthen its financial standing.